NCCN Recommendations for Dacomitinib (VIZIMPRO)
First-line treatment choice can impact treatment strategy
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for sensitizing EGFR mutation positive metastatic NSCLC†:
†This is not a comprehensive representation of NCCN recommendations.
‡Refer to the NCCN Guidelines for specific treatment recommendations for each setting. Not all agents in a drug class are recommended for each setting.
All non-systemic therapy treatments displayed above are NCCN Category 1 recommended.
VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.5.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed June 7, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.